The 40 most recent market catalysts affecting $ELV, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 14, 2026
Corporate Catalyst
Neutral
Impact 65
U.S. Senators Launch Inquiries with Health Insurers Regarding Prior Authorization Pledges
A group of U.S. Senators, led by Jon Ossoff, has initiated formal inquiries with six prominent health insurance providers, including Elevance Health, to scrutinize their follow-thr…
Oct 29, 2026
Corporate Catalyst
Bearish
Impact 55
UBS Adjusts Elevra Lithium Price Target
UBS, a major investment bank, has reduced its price target for Elevra Lithium by 2%. This action signals a slightly diminished outlook for the company's valuation and market standi…
Oct 27, 2026
Corporate Catalyst
Bearish
Impact 75
Senators Query Elevance Health Regarding CMS Data Requests and Coverage Terminations
U.S. senators have sent letters to Elevance Health and other major insurance companies, questioning their role in allegedly terminating coverage for hundreds of thousands of enroll…
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Markets Comments on Elevance Health's Medicaid and ACA Margin Outlook
This 8-K filing discloses RBC Capital Markets' positive commentary on Elevance Health's Medicaid and ACA segment margin outlook, indicating support for the company's earnings growt…
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Adjusts Price Target on Elevance Health to $500 From $475
Truist Financial has updated its valuation assessment for Elevance Health, leading to a revised price target of $500, up from $475. The firm also maintained its 'Buy' rating, signa…
Oct 22, 2026
Corporate Catalyst
Neutral
Impact 55
Multiple Financial Institutions Adjust Price Targets for Elevance Health
On October 22, 2026, multiple financial institutions, including Truist and UBS, revised their price targets for Elevance Health (ELV). Both Truist and UBS raised their targets and …
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Raises Price Target on Elevance Health to $500
Truist Securities, a prominent financial institution, has raised its price target on Elevance Health (ELV) to $500 from $475, maintaining a 'Buy' rating. This adjustment signals in…
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 55
Evercore ISI Adjusts Elevance Health Price Target to $460
Evercore ISI, a prominent investment bank, raised its price target for Elevance Health (ELV) to $460 from $430. This upward revision indicates that the analyst firm believes ELV's …
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 55
BofA Securities Adjusts Elevance Health Price Target to $500
BofA Securities has raised its price target for Elevance Health (ELV) from $480 to $500. This is a positive signal from a prominent investment bank, indicating a more optimistic ou…
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 55
Jefferies Adjusts Price Target on Elevance Health to $510 From $450
Jefferies, a prominent financial firm, has updated its financial outlook for Elevance Health, raising its price target on the company's stock. This adjustment from $450 to $510 is …
Oct 21, 2026
Corporate Catalyst
Bullish
Impact 65
Elevance Health Executive Says Q3 Medicaid Performance Was Ahead Of Outlook, Primarily Due To Recent Rate Actions; Expects Medicaid Margins To Improve In 2027 As Rates Become Better Aligned With Cost Trends
Elevance Health's executive commentary from a conference call revealed that the company's Q3 Medicaid performance surpassed its outlook, primarily driven by recent rate adjustments…
Oct 21, 2026
Corporate Catalyst
Neutral
Impact 75
Elevance Health FY2026 Adj EPS expected to be more than $29.00 vs $27.23 Est
Elevance Health (ELV) has provided forward-looking guidance indicating that its adjusted earnings per share for fiscal year 2026 will be more than $29.00. This figure is notably hi…
Oct 21, 2026
Corporate Catalyst
Neutral
Impact 85
Elevance Health FY2026 GAAP EPS expected to be more than $22.00 vs $20.74 Est
Elevance Health (ELV) has provided forward-looking guidance for its fiscal year 2026, projecting GAAP EPS to be more than $22.00. This figure is notably higher than the current ana…
Oct 21, 2026
Corporate Catalyst
Bullish
Impact 92
Elevance Health Q3 Adj. EPS $6.99 Beats $4.68 Estimate, Sales $50.440B Beat $49.213B Estimate
Elevance Health announced Q3 adjusted EPS of $6.99, significantly surpassing the $4.68 consensus estimate, representing a 49.36% beat and a 15.92% year-over-year increase. Quarterl…
Oct 8, 2026
Energy/Commodity
Bullish
Impact 75
Elevra Lithium Announces Binding Three-Year Contract To Supply 240,000 Tonnes Of Spodumene Concentrate To LG Energy Solution
This announcement is a significant development in the lithium and EV battery supply chain. For Elevra Lithium (ELV), securing a binding three-year contract for 240,000 tonnes of sp…
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on Elevance Health, Raises Price Target to $469
Barclays analyst Andrew Mok maintained an 'Overweight' rating on Elevance Health (ELV) and raised the price target from $457 to $469. This action indicates a positive outlook from …
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 75
Elevance Health Stock is Moving Higher After FY26 EPS Reaffirmation
Elevance Health (ELV) reaffirmed its full-year 2026 adjusted earnings guidance, including an underlying adjusted EPS of over $27.00, which is slightly above the analyst consensus. …
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 75
Elevance Health shares are trading higher after the company reaffirmed its FY26 GAAP and adjusted EPS guidance.
Elevance Health's reaffirmation of its FY26 GAAP and adjusted EPS guidance is a significant positive corporate catalyst. It provides clarity and confidence to investors regarding t…
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 65
Elevance Health Affirms FY2026 GAAP EPS expected to be more than $20.10 vs $20.26 Est
Elevance Health (ELV) affirmed its fiscal year 2026 GAAP EPS guidance, stating it expects earnings to be more than $20.10. This is a significant piece of information for investors …
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 75
Elevance Health Affirms FY2026 Adj EPS expected to be more than $27.00 vs $26.91 Est
Elevance Health (ELV) has affirmed its fiscal year 2026 adjusted EPS guidance, indicating it expects to achieve more than $27.00 per share. This is a positive development as it sur…
Aug 21, 2026
Energy/Commodity
Bullish
Impact 85
Elevra Lithium shares are trading higher after the company announced a binding Spodumene Concentrate Supply Agreement with Mangrove for the long-term supply of spodumene concentrate produced at North American Lithium in Québec.
This binding supply agreement is a significant corporate catalyst for Elevra Lithium (ELV), providing revenue visibility and de-risking its operations. For Mangrove (MNGV), it secu…
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 55
Leerink Partners Maintains Market Perform on Elevance Health, Raises Price Target to $395
Leerink Partners analyst Whit Mayo has maintained a 'Market Perform' rating on Elevance Health (ELV) but raised the price target from $364 to $395. This indicates that while the an…
Jul 16, 2026
Corporate Catalyst
Bearish
Impact 55
Wells Fargo Maintains Overweight on Elevance Health, Lowers Price Target to $473
Wells Fargo analyst Stephen Baxter has reiterated an 'Overweight' rating on Elevance Health (ELV), indicating a continued positive long-term view on the company's fundamentals. How…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 85
These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings
Elevance Health's Q2 earnings significantly surpassed analyst expectations, with adjusted earnings of $7.45 per share against an estimated $6.21, and revenue of $49.83 billion exce…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $455
Guggenheim analyst Jason Cassorla has raised the price target for Elevance Health (ELV) from $399 to $455 while maintaining a 'Buy' rating. This action indicates a positive outlook…
Jul 16, 2026
Corporate Catalyst
Bearish
Impact 55
Barclays Maintains Overweight on Elevance Health, Lowers Price Target to $457
Barclays analyst Andrew Mok maintained an 'Overweight' rating on Elevance Health (ELV), signaling continued confidence in the company's long-term prospects. However, the price targ…
Jul 15, 2026
Corporate Catalyst
Bearish
Impact 75
Shares of health insurance companies are trading lower amid sympathy with Elevance after the company reported Q2 financial results that indicated margin pressure.
Elevance's Q2 report, specifically the mention of margin pressure, acts as a significant corporate catalyst for the entire health insurance sector. The 'sympathy' selling suggests …
Jul 15, 2026
Corporate Catalyst
Bearish
Impact 75
Elevance Health shares are trading lower. The company reported Q2 financial results.
The headline directly points to Elevance Health's Q2 financial results as the cause for its share price decline. This is a clear corporate catalyst, indicating that the reported fi…
Jul 15, 2026
Corporate Catalyst
Neutral
Impact 75
Elevance Health Sees FY2026 GAAP EPS expected to be more than $20.10 vs $20.26 Est
Elevance Health (ELV) has released its initial guidance for Fiscal Year 2026 GAAP EPS, stating it expects earnings to be 'more than $20.10'. This is a significant disclosure as it …
Jul 15, 2026
Corporate Catalyst
Neutral
Impact 75
Elevance Health Sees FY2026 Adj EPS expected to be more than $27.00 vs $26.91 Est
Elevance Health (ELV) announced that its adjusted EPS for fiscal year 2026 is expected to exceed $27.00, which is higher than the analyst consensus of $26.91. This positive guidanc…
Jul 15, 2026
Corporate Catalyst
Bearish
Impact 92
Elevance Health Q2 Adj. EPS $7.45 Beats $6.21 Estimate, Sales $49.826B Beat $48.693B Estimate
Elevance Health (ELV) announced Q2 adjusted EPS of $7.45, significantly beating the $6.21 estimate, and sales of $49.826 billion, also exceeding the $48.693 billion estimate. This …
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains Buy on Elevance Health, Raises Price Target to $465
TD Cowen analyst Ryan Langston has maintained a 'Buy' rating on Elevance Health (ELV) and raised the price target from $400 to $465. This action signals increased confidence from t…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Elevance Health, Raises Price Target to $475
Truist Securities analyst David Macdonald maintained a 'Buy' rating on Elevance Health (ELV) and raised the price target from $450 to $475. This action signals continued confidence…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Elevance Health, Raises Price Target to $492
Wells Fargo analyst Stephen Baxter has maintained an 'Overweight' rating on Elevance Health (ELV) and raised the price target from $391 to $492. This action signals a strong vote o…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.